MAGEA3 anticorps (AA 283-314)

N° du produit ABIN7873309

Cet anticorps anti-MAGEA3 Polyclonal Lapin (ABIN7873309) détecte spécifiquement MAGEA3 dans WB, FACS et IHC (p). L’anticorps est réactif avec des échantillons de Humain.

Aperçu rapide pour MAGEA3 anticorps (AA 283-314) (ABIN7873309)

Antigène: MAGEA3 (Melanoma Antigen Family A, 3 (MAGEA3))

Reactivité: Humain

Hôte: Lapin

Clonalité: Polyclonal

Conjugué: Cet anticorp MAGEA3 est non-conjugé

Application: Western Blotting (WB), Flow Cytometry (FACS), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))

Détail du produit anti-MAGEA3 anticorps

Épitope: AA 283-314

Fonction: MAGE3 Antibody / Melanoma-associated antigen 3

Immunogène: A portion of amino acids 283-314 from the human protein was used as the immunogen for the MAGE3 antibody.

Isotype: Ig Fraction

Information d'application

Indications d'application: The stated application concentrations are suggested starting points. Titration of the MAGE3 antibody may be required due to differences in protocols and secondary/substrate sensitivity.

Restrictions: For Research Use only

Stockage

Format: Liquid

Buffer: In 1X PBS, pH 7.4, with 0.09 % sodium azide

Agent conservateur: Sodium azide

Précaution d'utilisation: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Stock: -20 °C

Stockage commentaire: Aliquot the MAGE3 antibody and store frozen at -20oC or colder. Avoid repeated freeze-thaw cycles.

Détails sur MAGEA3

Antigène: MAGEA3 (Melanoma Antigen Family A, 3 (MAGEA3))

Autre désignation: MAGE3

Sujet: MAGE3, also known as Melanoma-associated antigen 3, is a protein that is commonly expressed in melanoma cells. It plays a crucial role in tumor growth and progression, making it an attractive target for cancer therapy. Research has shown that targeting MAGE3 can effectively inhibit the growth of melanoma cells, leading to the potential development of new treatments for this aggressive form of cancer. One of the most exciting aspects of MAGE3 is its ability to stimulate the immune system to recognize and attack cancer cells. This makes it a promising candidate for immunotherapy, a cutting-edge treatment that harnesses the power of the body's own immune system to fight cancer. By targeting MAGE3, researchers hope to develop more effective and targeted therapies for melanoma patients. Recent studies have highlighted the potential of MAGE3 as a biomarker for predicting the prognosis of melanoma patients. By measuring the levels of MAGE3 in tumor samples, doctors can better tailor treatment plans and improve patient outcomes.

UniProt: P43357